Cytokine Signalling Forum

Publications





January 19

Riesgo Comparativo de Tromboembolismo Venoso con Tofacitinib versus con Inhibidor de Factor de Necrosis Tumoral: Un Estudio de Cohorte de Pacientes con Artritis Reumatoide

Desai RJ, Pawar A, Weinblatt ME, Kim SC.
Desai RJ, et al. Arthritis Rheumatol. 2019 June;71(6):892-900.

Occurrences of venous thromboembolism (VTE) in 50, 865 RA patients initiating Tofacitinib (TOF) or a TNF inhibitor (TNFi) was infrequent. No significant risk of VTE for TOF versus TNFi was observed. Safety concerns of JAK inhibitor BARI include potentially increased risk of VTE at the higher 4 mg dose. It’s unclear if this is attributable to JAK-inhibition and extends to TOF. This study compared the risk of VTE with TOF, versus TNFi in real-world settings with RA patients. RA patients in...

Keywords: JAK, Tofacitinib, Clinical, Safety

Translated by: Igor